Tyra Biosciences (TYRA) Accounts Payables (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Accounts Payables data on file, last reported at $3.6 million in Q1 2026.

• Quarterly Accounts Payables rose 45.68% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 45.68% YoY) and the FY2025 annual result came in at $1.2 million, up 99.66% from the prior year.
• Accounts Payables rose to $3.6 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.7 million in Q4 2023 to a low of $590000.0 in Q4 2024.
• A 5-year average of $2.1 million and a median of $2.0 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 307.16% — and 2024, when it slumped 87.34%.
• Tracing TYRA's Accounts Payables over 5 years: stood at $1.1 million in 2022, then surged by 307.16% to $4.7 million in 2023, then tumbled by 87.34% to $590000.0 in 2024, then jumped by 99.66% to $1.2 million in 2025, then soared by 209.17% to $3.6 million in 2026.
• The last three Accounts Payables figures came in at $3.6 million (Q1 2026), $1.2 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.